Daiwa Securities upgrades rating on Vertex Pharmaceuticals amid institutional trading
1 report, 1 independent
Updated Sun 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Sumitomo Mitsui Trust Group Inc. reduced its stake in Vertex Pharmaceuticals Incorporated by 2.9% during the third quarter. Separately, Daiwa Securities Group upgraded its rating and increased the target price for Vertex Pharmaceuticals stock. The firm owned about 0.23% of Vertex Pharmaceuticals as of its most recent filing.
From themarketsdaily.com
Why it matters
The activity reflects continued institutional interest in Vertex Pharmaceuticals, which is currently owned by 90.96% of hedge funds and institutional investors. Daiwa Securities Group's rating change suggests a positive market outlook for the pharmaceutical company.
From themarketsdaily.com
Who's involved
- Vertex PharmaceuticalsAmerican pharmaceutical company whose stock was subject to rating changes and stake trimming.
- Daiwa Securities GroupProvided an upgraded rating and increased target price for Vertex Pharmaceuticals.
Keep exploring
The entities involved
-
Vertex Pharmaceuticals
American pharmaceutical company
-
Daiwa Securities Group
public company
Nothing else this week.